Stereotaxis, Inc. (STXS) Form 8-K — Aug 11, 2026
Stereotaxis reported second quarter 2026 revenue of $7.7 million, down from $8.8 million a year earlier, with a net loss of $4.5 million versus $3.8 million in the prior-year quarter. System revenue fell to $1.5 million with no robotic system delivery in the quarter, while recurring revenue rose to $6.2 million from $5.8 million. Management framed the quarter as a commercial inflection point: robotic catheter revenue exceeded $1 million with 270% sequential growth, a US hospital made the first GenesisX purchase with installation planned this fall, and multiple Synchrony digital operating room systems were sold following April FDA clearance.
Key figures
- Revenue
- 7670000
- Guidance
- Recurring revenue of approximately $7 million in Q3 2026 and $8 million in Q4 2026; system revenue of approximately $3 million in each of Q3 and Q4; cash flow profitability anticipated in the first half of 2027.
- Revenue Yoy
- -12.8% (from $8.8 million in Q2 2025)
- Total Assets
- 55582000
- Cash Position
- 10491000
- Debt
- no debt
- Gross margin
- 58%
- System revenue
- 1479000
- Cash dec 31 2025
- 13421000
- Adjusted net loss
- -2000000
- Recurring revenue
- 6191000
- Operating expenses
- 9054000
- System gross margin
- 29%
- Common shares issued
- 97938091
- Prior year q2 revenue
- 8798000
- Recurring gross margin
- 66%
- Robotic catheter revenue
- over $1 million, +270% sequentially
- Total stockholders equity
- 12243000
- Adjusted operating expenses
- 6600000
- Weighted avg diluted shares
- 100031760
Price after filing
Close on the filing date to close N calendar days later (from $1.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.